Compare MORN & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | BAX |
|---|---|---|
| Founded | 1984 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.4B |
| IPO Year | 2005 | N/A |
| Metric | MORN | BAX |
|---|---|---|
| Price | $216.21 | $18.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 10 |
| Target Price | ★ $333.33 | $27.00 |
| AVG Volume (30 Days) | 359.2K | ★ 9.1M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.85% | 0.21% |
| EPS Growth | ★ 16.18 | N/A |
| EPS | ★ 8.80 | N/A |
| Revenue | $2,395,400,000.00 | ★ $11,023,000,000.00 |
| Revenue This Year | $8.52 | $5.72 |
| Revenue Next Year | $7.45 | $2.52 |
| P/E Ratio | $24.47 | ★ N/A |
| Revenue Growth | ★ 7.76 | 3.90 |
| 52 Week Low | $202.89 | $17.40 |
| 52 Week High | $365.00 | $37.74 |
| Indicator | MORN | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 44.45 |
| Support Level | $205.97 | $17.40 |
| Resistance Level | $215.23 | $18.95 |
| Average True Range (ATR) | 4.04 | 0.55 |
| MACD | 1.07 | 0.25 |
| Stochastic Oscillator | 76.89 | 86.13 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.